

Indices	Current Value	% 1 D	% YTD
Sensex	84,680	-0.6	8.4
Nifty	25,860	-0.6	9.4
BSE Midcap	46,192	-0.8	-0.5
BSE Small cap	50,744	-0.7	-8.0

**Sectors – Performance (BSE)**

Telecom	3,098	0.7	8.8
Consumer Dur	60,515	0.5	-6.1
FMCG	20,127	-0.0	-3.1
Realty	6,790	-1.4	-17.5
Bankex	66,025	-1.0	14.3
IT	36,783	-0.9	-14.8

Nifty Gainers/Losers	CMP	% Chg
TITAN	3,930	1.6
BHARTIARTL	2,102	1.6
TATACONSUM	1,170	1.1
AXISBANK	1,220	(5.1)
JSWSTEEL	1,083	(2.9)
HCLTECH	1,652	(1.9)

**FII Trading activities in Cash**

	Date	Net	MTD
FII	16-Dec-25	-2,061	-3,488
DII	16-Dec-25	771	2,506

Figs. in Rs Cr.

Global Indices	Current Value	% 1 D	% YTD
Dow Jones	48,114	(0.6)	13.1
Nasdaq	23,111	0.2	19.7
DAX	24,077	(0.6)	20.9
Nikkei 225	49,370	(0.0)	23.8
FTSE 100	9,685	(0.7)	18.5
Hang Seng	25,169	(0.3)	25.5
Shanghai	3,818	(0.2)	13.9

**Forex Rate**

INR/USD	91.0	-0.3	-6.0
INR/EUR	107.0	-0.4	-16.6
INR/GBP	122.1	-0.5	-11.9
INR/YEN (100)	58.8	-0.4	-7.0

Source: Bloomberg

**Market Commentary**

- **Asian markets** are trading in the green as investors assess Japan's trade data while remaining cautious on global macro cues. The Nikkei, Hang Seng, and Shanghai are trading higher by 0.18%, 0.15%, and 0.20%, respectively.
- **Indian indices** are poised for a positive opening. GIFT Nifty was trading at 25,931 compared to yesterday's Nifty Futures close of 25,941.
- **U.S. markets** ended mixed as investors digested shaky economic data, raising fresh concerns over the growth outlook and the Fed's policy path. Dow Jones ended lower by 302 points or 0.62% to close at 48,114, and NASDAQ ended higher by 54 points or 0.23% to close at 23,111.

**News in Focus**

- **Glenmark Pharma:** The company's arm signed a pact with Hansoh Pharma to develop and commercialise Aumolertinib. Aumolertinib is an inhibitor indicated to treat non-small cell lung cancer.
- **NBCC:** The company received orders totalling Rs 345 Cr, including a Rs 333 Cr contract from IIT Mandi for the construction of academic blocks, and a Rs 12 Cr order from Kandia SEZ for annual maintenance work.
- **Saregama India:** The company plans to acquire a 51% stake in Bhansali Productions in tranches by 2030. Bhansali Productions will exclusively sell all future films' music to the company.
- **HCLTech:** The company has partnered with NSE Academy to deliver a series of joint certificate programs in tech, finance sectors.
- **Protean eGov Tech:** The board has approved the acquisition of a 4.95% stake in NSDL Payments Bank for Rs 30.2 Cr.
- **Thermax:** The company's arm, First Energy, incorporated a step-down arm, First Energy 15.
- **TCS:** The company's arm, ListEngage MidCo LLC, forms wholly owned arms, TCS North America Corp and Trident LE LLC in the US.
- **Kaynes Tech:** The company's arm partners with Mitsui & Co. and AOI Electronics to bolster semiconductor manufacturing operations in India.
- **Waaree Renewable Tech:** The company signed a long-term power purchase pact for a 300 MW interstate transmission system solar power project.
- **Acme Solar:** The company's arm commissioned additional capacity of 8MW out of a 100 MW wind power project in Gujarat.
- **Vikram Solar:** The board approved capex worth Rs 4,371 Cr for phase-1 of the battery energy storage system roadmap. The capex is to be undertaken via Arm VSL Powerhive, which will be funded via both equity and debt.
- **NTPC Green Energy:** The company's arm started commercial operations of 243.7 MW out of 1255 MW Khavda-I Solar PV Project in Gujarat.
- **Lupin:** Nagpur Injectable unit received an EIR report from the US FDA with Voluntary Action Indicated classification. The US FDA had inspected the Nagpur unit from 8th September to 16th September.
- **CESC:** The company's arm signed a pact with Toolfab for the supply of Towers for wind turbine generators. The company supplies 91 towers for 300 MW wind power projects within 12 months.
- **Diamond Power Infra:** The company received a letter of Intent for a Rs 57.6 Cr order from Rajesh Power for the supply of cables.
- **Ahluwalia Contracts:** The company received a Rs 888 Cr order from the Bihar State Tourism Development Corp for EPC works. Additionally, it received an order for the construction of Ram Janmabhoomi Tirtha Kshetra at Sitamarhi District.
- **Coal India:** The Coal Ministry extended an additional charge for the post of Chairman, MD to B. Sairam for six Months.
- **Wockhardt:** The company's arm incorporated three wholly owned arms, Wockhardt Swiss AG, Wockhardt Suisse USA Holding Corp and Wockhardt Suisse USA.

**Axis Intellect: Intraweek Stocks for the week 15<sup>th</sup> Dec 2025 to 22<sup>nd</sup> Dec 2025**

<b>Name of Stock</b>	<b>Mcap</b>	<b>Sector</b>
HINDUSTAN AERONAUTICS LIMITED	Large Cap	Industrials
UNION BANK OF INDIA	Large Cap	Banks
FORTIS HEALTHCARE LTD	Mid Cap	Healthcare
ULTRATECH CEMENT LTD	Large Cap	Build Mate
VARUN BEVERAGES LIMITED	Large Cap	Staples
RELIANCE INDUSTRIES LTD	Large Cap	Oil & gas
SYRMA SGS TECHNOLOGY LIMITED	Small Cap	Industrials
SUN PHARMACEUTICAL INDUSTRIES LTD.	Large Cap	Healthcare
DEEPAK NITRITE LIMITED	Mid Cap	Agri & Chem
INFOSYS LTD	Large Cap	IT

## Investment Picks

Company	Recommendation	CMP	Target Price	% Upside
Aarti Drugs Ltd	BUY	387	610	57.6
Aarti Industries Ltd	BUY	372	530	42.5
ACC Ltd	BUY	1,772	2,390	34.9
Affle 3I Ltd	BUY	1,718	2,200	28.1
Ambuja Cements Ltd	BUY	549	705	28.5
APL Apollo Tubes Ltd	BUY	1,740	2,100	20.7
Aptus Value Housing Finance India Ltd	BUY	289	405	40.0
Arvind Smartspaces Ltd	BUY	605	940	55.4
Astral Ltd	BUY	1,460	1,750	19.9
Aurobindo Pharma Ltd	BUY	1,175	1,345	14.5
Avenue Supermarts Ltd	BUY	3,861	4,960	28.5
Bajaj Finance Ltd	BUY	997	1,200	20.3
Bank of Baroda Ltd	BUY	282	325	15.1
Bharti Airtel Ltd	BUY	2,105	2,530	20.2
Biocon Ltd	BUY	384	450	17.2
Birla Corporation Ltd	BUY	1,074	1,560	45.3
Britannia Industries Ltd	BUY	6,051	6,750	11.6
CCL Products (India) Ltd	BUY	982	1,140	16.1
Cera Sanitaryware Ltd.	BUY	5,360	7,900	47.4
Chalet Hotels Ltd.	BUY	879	1,120	27.4
Cholamandalam Investment & Finance Company Ltd	BUY	1,707	1,880	10.1
CIE Automotive India Ltd	BUY	396	500	26.2
Cipla Ltd	BUY	1,500	1,700	13.3
Coforge Ltd	BUY	1,862	2,300	23.5
Colgate-Palmolive (India) Ltd	BUY	2,158	2,570	19.1
CreditAccess Grameen Ltd	BUY	1260	1,685	33.7
Dabur India Ltd	BUY	496	590	18.9
Dalmia Bharat Ltd	BUY	2,066	2,550	23.4
DCB Bank Ltd	BUY	168	200	19.2
Dhanuka Agritech Ltd	BUY	1,193	1,640	37.5
DOMS Industries Ltd	BUY	2,549	3,110	22.0
Elecon Engineering Compan Ltd	BUY	480	635	32.3
Embassy Office Parks REIT	BUY	444	490	10.5
Equitas Small Finance Bank Ltd	BUY	58	69	18.5
Fortis Healthcare Ltd	BUY	872	1,070	22.8
G R Infraprojects Ltd	BUY	1,037	1,420	36.9
Genus Power Infrastructures Ltd	BUY	300	430	43.2
Gland Pharma Ltd	BUY	1,665	2,170	30.3
Global Health Ltd	BUY	1,141	1,400	22.7
Gravita India Ltd	BUY	1,850	2,500	35.1
Greenply Industries Ltd.	BUY	275	385	40.0
H. G. Infra Engineering Ltd	BUY	754	1,255	66.5
Happiest Minds Technologies Ltd.	BUY	489	690	41.1
HDFC Bank Ltd	BUY	994	1,170	17.7
HealthCare Global Enterprises Ltd	BUY	722	850	17.8
ICICI Bank Ltd	BUY	1,367	1,650	20.7
Indian Hotels Company Ltd	BUY	724	835	15.4
Inox Wind Ltd	BUY	127	190	50.1
ITC Ltd	BUY	402	480	19.4
J.Kumar Infraprojects Ltd	BUY	549	775	41.1
JK Lakshmi Cement Ltd	BUY	779	1,030	32.2
JSW Energy Ltd.	BUY	478	705	47.6
K E C International Ltd	BUY	704	1,030	46.3
Kalpataru Projects International Ltd.	BUY	1,162	1,475	26.9

## Investment Picks

Company	Recommendation	CMP	Target Price	% Upside
Kirloskar Brothers Ltd	BUY	1,643	2,330	41.8
Kotak Mahindra Bank Ltd	BUY	2,184	2,575	17.9
KPIT Technologies Ltd	BUY	1,167	1,350	15.7
Krishna Institute of Medical Sciences Ltd	BUY	659	795	20.7
Lupin Ltd	BUY	2,086	2,400	15.1
Mahanagar Gas Ltd	BUY	1,285	1,540	19.8
Man Infraconstruction Ltd.	BUY	129	190	47.6
Maruti Suzuki India Ltd	BUY	16,326	18,170	11.3
MAS Financial Services Ltd	BUY	318	380	19.4
Max Healthcare Institute	BUY	1,070	1,425	33.2
Minda Corporation Ltd	BUY	597	690	15.6
Mold-Tek Packaging Ltd	BUY	577	850	47.2
Nestle India Ltd	BUY	1,242	1,410	13.6
Nippon Life India Asset Management Ltd	BUY	866	1,000	15.5
NLC India Ltd	BUY	240	310	29.2
NTPC Ltd	BUY	320	400	24.9
Pitti Engineering Ltd	BUY	803	1,335	66.4
Prestige Estates Projects Ltd	BUY	1,625	2,000	23.1
Prince Pipes and Fittings Ltd	BUY	254	400	57.6
Rainbow Children's Medicare Ltd.	BUY	1,335	1,625	21.7
Rites Ltd	BUY	225	280	24.4
Sansera Engineering Ltd	BUY	1,711	1,950	14.0
SBI Cards & Payment Services Ltd	BUY	845	1,035	22.6
Shree Cement Ltd	BUY	26,000	31,655	21.8
Signatureglobal (India) Ltd	BUY	1,120	1,400	25.0
Skipper Ltd	BUY	439	580	32.2
Star Cement Ltd	BUY	220	335	52.6
State Bank of India	BUY	960	1,135	18.2
Steel Strips Wheels Ltd	BUY	192	265	37.8
Tata Steel Ltd	BUY	170	195	14.8
Trent Ltd	BUY	4,111	5,100	24.1
TVS Motor Company Ltd	BUY	3,620	4,000	10.5
Ujjivan Small Finance Bank Ltd	BUY	54	65	20.6
UltraTech Cement Ltd	BUY	11,520	13,900	20.7
V Mart Retail Ltd	BUY	762	900	18.1
VA Tech Wabag Ltd.	BUY	1,289	1,930	49.7
Varun Beverages Ltd	BUY	476	565	18.8
Welspun Living Ltd	BUY	135	165	21.8
Westlife Foodworld Ltd	BUY	531	650	22.4

## Trading Insights

### Insight from trading volumes

Script	CMP	Total Volume (x1000)	Monthly Avg Volume(x1000)	% Change
AXIS BANK LTD	1,220	11,698	5,126	128.2%
INDIAN OIL CORP LTD	168	28,365	12,726	122.9%
TITAN CO LTD	3,930	1,574	758	107.6%
LARSEN & TOUBRO LTD	4,064	2,223	1,557	42.8%
ITC LTD	402	12,970	9,346	38.8%
COAL INDIA LTD	382	5,925	4,385	35.1%
ICICI BANK LTD	1,366	12,478	10,059	24.1%

### Insight from delivery

Script	CMP	Total Delivery Volume(x1000)	Monthly Avg Delivery Volume(x1000)	%Change
SHREE CEMENT LTD	25,990	57	27	112.3%
INDIAN OIL CORP LTD	168	12,739	6,646	91.7%
GRASIM INDUSTRIES LTD	2,799	577	323	78.6%
BAJAJ AUTO LTD	9,008	322	229	40.5%
NTPC LTD	321	7,230	5,153	40.3%
TATA STEEL LTD	170	17,259	12,508	38.0%
KOTAK MAHINDRA BANK LTD	2,182	2,420	2,652	-8.8%

\*CMP-Closing Market Price

Axis Direct is the brand under Axis Securities Limited, which is a 100% subsidiary of Axis Bank Limited. Axis Bank Ltd. is a listed public company and one of India's largest private sector banks, and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on [www.axisbank.com](http://www.axisbank.com).

Axis Securities Limited is registered as a

- Stock Broker, Depository Participant, Portfolio Manager, Investment Adviser and Research Analyst with the Securities and Exchange Board of India
- Corporate Agent with Insurance Regulatory and Development Authority of India
- Point of Presence with Pension Fund Regulatory and Development Authority
- Distributor for Mutual Funds with AMFI

Registration Details:

SEBI Single Reg. No.- NSE, BSE, MSEI, MCX & NCDEX – INZ000161633 | SEBI Depository Participant Reg. No. IN-DP-403-2019 | Portfolio Manager Reg. No.- INP000000654 | Investment Advisor Reg No. INA000000615 | SEBI-Research Analyst Reg. No. INH000000297 | IRDA Corporate Agent (Composite) Reg. No. CA0073| PFRDA – POP Reg. No. POP387122023 | Mutual Fund Distributor ARN- 64610.

Compliance Officer Details: Name – Mr Rajiv Kejriwal, Tel No. – 022-68555574, Email id – [compliance.officer@axisdirect.in](mailto:compliance.officer@axisdirect.in);

Registered Office Address – Axis Securities Limited, Unit No.002, Building- A, Agastya Corporate Park, Piramal Realty, Kamani Junction, Kurla (W), Mumbai – 400070.

Administrative office address: Axis Securities Limited, Aurum Q Parç, Q2 Building, Unit No. 1001, 10th Floor, Level – 6, Plot No. 4/1 TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai, Pin Code – 400710.

In case of any grievances, please call us at 022-40508080 or write to us at [helpdesk@axisdirect.in](mailto:helpdesk@axisdirect.in).

We hereby declare that our activities have neither been suspended nor have we defaulted with any stock exchange authority with whom we are registered in the last five years. However, SEBI, Exchanges, Clearing Corporations and Depositories, etc. have conducted the routine inspection and based on their observations have issued advice/warning/show cause notices/deficiency letters/ or levied penalty or imposed charges for certain deviations observed in inspections or in the normal course of business, as a Stock Broker/Depository Participant/Portfolio Manager. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point in time.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

By referring to any particular sector, Axis Securities does not provide any promise or assurance of a favourable view for a particular industry or sector or business group in any manner.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors. Our research should not be considered as an advertisement or advice, professional or otherwise. This research report and its respective content by Axis Securities made available on this page or otherwise do not constitute an offer to sell or purchase or subscribe for any securities or solicitation of any investments or investment services for the residents of Canada and/or the USA or any jurisdiction where such an offer or solicitation would be illegal.

Subject company(ies) may have been clients during the twelve months preceding the date of distribution of the research report. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment of its original date of publication by ASL and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

The information and opinions in this report have been prepared by Axis Securities and are subject to change without notice. The report and information contained herein are strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Axis Securities. The report must not be used as a singular basis for any investment decision. The views herein are of a general nature and do not consider the risk appetite, investment objective or the particular circumstances of an individual investor. The investor is requested to take into consideration all the risk factors, including their financial condition, suitability to risk return profile and the like and take professional advice before investing.

While we would endeavour to update the information herein on a reasonable basis, Axis Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Axis Securities from doing so. Non-rated securities indicate that the rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Axis Securities policies, in circumstances where Axis Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained in good faith from public sources and sources believed to be reliable, but no independent verification has been made, nor is its accuracy or completeness guaranteed. This report and information herein are solely for informational purposes and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Axis Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances.

The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and the needs of the specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Axis Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see the Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Axis Securities or its associates might have managed or co-managed a public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. Axis Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. Axis Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking, or brokerage services from the companies mentioned in the report in the past twelve months. Axis Securities encourages independence in research report preparation and strives to minimise conflict in the preparation of research reports. Axis Securities or its associates, or its analysts, did not receive any compensation or other benefits from the companies mentioned in the report or a third party in connection with the preparation of the research report. Accordingly, neither Axis Securities nor Research Analysts and/or their relatives have any material conflict of interest at the time of publication of this report. Please note that Axis Securities has a proprietary trading desk. This desk maintains an arm's length distance from the Research team, and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Research Analyst may have served as an officer, director or employee of the subject company(ies). Axis Securities or Research Analysts, or their relatives, do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of Axis Securities and Axis Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one per cent or more or other material conflicts of interest in various companies, including the subject company/companies mentioned in this report. Axis Securities may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report. Certain transactions-including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centre on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender/borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Axis Securities may have proprietary long/short positions in the above-mentioned scrip(s) and therefore may be considered as interested. This should not be construed as an invitation or solicitation to do business with Axis Securities. Axis Securities is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independently of the PCG research, and accordingly, PMS may have positions contrary to the PCG research recommendation.

This research report is issued in India by Axis Securities Limited in accordance with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. It is intended solely for persons residing in India. The report is not directed at or intended for distribution to, or use by, any person or entity resident in the United States of America, Canada, or in any jurisdiction where such distribution, publication, availability, or use would be contrary to applicable securities laws, including the U.S. Securities Exchange Act of 1934, regulations of the U.S. Securities and Exchange Commission (SEC), and regulations of the Canadian Securities Administrators (CSA).